Veradermics, Incorporated
MANE
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.47B
Close$
$0.62
99.5% downside
Current Fair Value
99.5% downsideOvervalued by 99.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.47 Billion |
|---|---|
| Enterprise Value | $5.15 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.38 |
| Beta | 1.23 |
| Outstanding Shares | 40,436,000 |
Return
| Return on Equity | -9.62% |
|---|---|
| Return on Assets | -9.48% |
| Return on Invested Capital | -10.78% |
Valuation & Multiples
| P/E Ratio | -61.17 |
|---|---|
| PEG | -19.4 |
| Price to Sales | - |
| Price to Book Ratio | 5.75 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -58.66 |
| Enterprise Value to Net Income | -66 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 2, 2026
EPS Estimate
$-0.67
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 10, 2026
EPS Estimate
$-0.59
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 84.35% |
|---|---|
| Total Invested | $805,088▼ 99.98% |
| Investors Holding | 6▼ 160.00% |
ESG Score
No data
About Veradermics, Incorporated
21 employees
CEO: Reid Waldman Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. Th...